WO2017052271A1 - Composition pour prévenir ou traiter la perte des cheveux - Google Patents

Composition pour prévenir ou traiter la perte des cheveux Download PDF

Info

Publication number
WO2017052271A1
WO2017052271A1 PCT/KR2016/010664 KR2016010664W WO2017052271A1 WO 2017052271 A1 WO2017052271 A1 WO 2017052271A1 KR 2016010664 W KR2016010664 W KR 2016010664W WO 2017052271 A1 WO2017052271 A1 WO 2017052271A1
Authority
WO
WIPO (PCT)
Prior art keywords
hair loss
plant
caffeine
pharmaceutical composition
extracellular vesicles
Prior art date
Application number
PCT/KR2016/010664
Other languages
English (en)
Korean (ko)
Inventor
이원종
최은욱
김수
우은영
박은주
김지현
정수영
Original Assignee
㈜프로스테믹스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ㈜프로스테믹스 filed Critical ㈜프로스테믹스
Publication of WO2017052271A1 publication Critical patent/WO2017052271A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9794—Liliopsida [monocotyledons]

Definitions

  • Hair is maintained by repeating hair growth and hair loss in cycles of anagen, catagen, and telogen.
  • anagen which grows hair
  • catagen which is the end of growth and shrinking of the hair follicles
  • talogen which is the time when the nipple stops working and the hair stays in the scalp. It can be divided into a generator, which is a time to start or to dehair old hair by generating new hair.
  • the hair grows naturally for men 3 to 5 years, for women 4 to 6 years, then for 30 to 45 days of degeneration, and for 3 to 4 months after the rest period. At the end of the off-season, the generator starts producing new hair.
  • Hair loss is a normal phenomenon, but a normal person has a lot of hair in the growth phase, while alopecia usually has a lot of hair in the resting phase, which causes visible hair loss.
  • Androgenetic alopecia develops male sexual characteristics and is caused by a male hormone called testosterone, a hormone that acts on the development of muscles and the development of male organs during puberty, and this testosterone is called 5 alpha-reductase.
  • testosterone a hormone that acts on the development of muscles and the development of male organs during puberty
  • 5 alpha-reductase a male hormone that acts on the development of muscles and the development of male organs during puberty
  • DHT Dihydrotestosterone
  • the enzyme is changed to Dihydrotestosterone (DHT)
  • DHT Dihydrotestosterone
  • the method of inhibiting the production of DHT by 5 alpha-reductase is mainly used to treat alopecia caused by this cause.
  • minoxidil has been reported to cause sticky feeling and irritation to the skin
  • finasteride is currently used as an oral preparation, but side effects such as sexual dysfunction are reported depending on its intake. It is effective only when a steady dose is taken against hair loss, and these 5 alpha-reductase activity inhibitors are difficult to expect the effect by application, and can be expected only by oral administration, so there is a lot of inconvenience in use.
  • the diameter of the extracellular vesicles may be 30 ⁇ 1,000nm.
  • the mixing ratio of the extracellular vesicles and caffeine is not particularly limited, but preferably 1: 1 to 10, or 1: 2 to 8, or 1: 3 to 7, or 1: 4 to 6, or 1: It may be included in a weight ratio of 4 to 5.
  • the diameter of the extracellular vesicles may be 30 ⁇ 1,000nm.
  • the content of the caffeine in the present invention is not particularly limited, but may preferably be included in an amount of 25 ⁇ 50 ⁇ M.
  • the step of obtaining a plant juice by juice the plants using a screw the step of obtaining a plant juice by juice the plants using a screw
  • the present invention may further perform the step of removing impurities by washing the plant, if necessary, prior to juice the plant.
  • a low-speed screw having a stirring speed of 20 to 100 rpm in the present invention because it can obtain a plant juice containing a large amount of extracellular vesicles having excellent hair growth and hair growth effects.
  • the stationary culture may be performed for 12 to 48 hours at 20 to 30 °C.
  • the centrifugation is performed first at 100 to 500 g for 10 to 30 minutes, and secondly at 1,000 to 2,000 g for 10 to 30 minutes, then at 5,000 to 20,000 g for 30 minutes to 1 hour. Can be performed by car.
  • the filtration may be performed one or more times using a filtration membrane containing pores having an average pore size of 0.2 ⁇ 0.5 ⁇ m.
  • the first filtration is performed using a filtration membrane including pores having an average pore size of 0.4 to 0.5 ⁇ m
  • the second filtration is performed using a filtration membrane including pores having an average pore size of 0.2 to 0.3 ⁇ m. It is possible to obtain a filtrate containing a large amount of extracellular cell bodies having excellent hair growth and hair growth effects.
  • the step of obtaining a plant juice by juice the plant using a screw the step of obtaining a plant juice by juice the plant using a screw
  • It provides a method for preparing a cosmetic composition for improving hair loss, comprising the step of mixing caffeine in the filtrate.
  • the present invention may further perform the step of removing impurities by washing the plant, if necessary, prior to juice the plant.
  • the stationary culture may be performed for 12 to 48 hours at 20 to 30 °C.
  • the centrifugal separation may be performed at least once for 10 to 120 minutes at 100 to 20,000 g.
  • the centrifugation is performed first at 100 to 500 g for 10 to 30 minutes, and secondly at 1,000 to 2,000 g for 10 to 30 minutes, then at 5,000 to 20,000 g for 30 minutes to 1 hour. Can be performed by car.
  • the mixing ratio of the filtrate and caffeine in the present invention is not particularly limited, but preferably 1: 1 to 10, or 1: 2 to 8, or 1: 3 to 7, or 1: 4 to 6, or 1: It may be included in a weight ratio of 4 to 5.
  • the step of obtaining a plant juice by juice the plant using a screw the step of obtaining a plant juice by juice the plant using a screw
  • the present invention may further perform the step of removing impurities by washing the plant, if necessary, prior to juice the plant.
  • the stationary culture may be performed for 12 to 48 hours at 20 to 30 °C.
  • the centrifugal separation may be performed at least once for 10 to 120 minutes at 100 to 20,000 g.
  • the centrifugation is performed first at 100 to 500 g for 10 to 30 minutes, and secondly at 1,000 to 2,000 g for 10 to 30 minutes, then at 5,000 to 20,000 g for 30 minutes to 1 hour. Can be performed by car.
  • extracellular vesicles refers to small vesicles of membrane structure secreted from various cells, also defined as nanovesicles (nanovesicle).
  • the extracellular vesicles have a diameter of approximately 30 to 1,000 nm, preferably an average diameter of 100 to 300 nm, and mean a vesicle that is released into the extracellular environment by fusion of the polycystic body with the plasma membrane.
  • plant is understood as meaning including both mature plants as well as plant cells, plant tissues and seeds of plants that can develop into mature plants.
  • plant juice refers to a liquid fluid obtained by flowing out moisture contained in the inside of the plant by mechanical force or rotational force to the outside, for example, juice, vegetable juice, plant Juice, etc., but is not limited thereto.
  • the pharmaceutical composition may further include a suitable carrier, excipient or diluent according to a conventional method.
  • Carriers, excipients and diluents that may be included in the pharmaceutical compositions of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium Silicates, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, methylhydroxy benzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil and the like can be used, but are not limited thereto.
  • compositions according to the present invention may be formulated in the form of oral dosage forms, external preparations, suppositories, or sterile injectable solutions, such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, respectively, according to a conventional method.
  • sterile injectable solutions such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, and aerosols, respectively, according to a conventional method.
  • it may be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrating agents, surfactants, and the like.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient such as starch, calcium carbonate, in the pharmaceutical composition of the present invention.
  • excipients such as starch, calcium carbonate, in the pharmaceutical composition of the present invention.
  • Sucrose, lactose, gelatin and the like can be mixed and prepared.
  • lubricants such as magnesium stearate, talc can also be used.
  • Liquid preparations for oral use include suspensions, solvents, emulsions, and syrups, and include various excipients such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. Can be.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories.
  • non-aqueous solvent and suspending agent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used.
  • base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
  • the amount may be added at a ratio of 0.1 to 50% of the total weight.
  • natural carbohydrates include monosaccharides such as glucose, disaccharides such as fructose, sucrose and the like, and common sugars such as polysaccharides, dextrins and cyclodextrins, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • the flavourant include natural flavourants (tautin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.), synthetic flavors (saccharin, aspartame, etc.).
  • compositions of the present invention include various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners. , pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like.
  • additives can be used independently or in combination.
  • the proportion of such additives is not so critical but is generally selected in the range of 0.1 to about 50 parts by weight per 100 parts by weight of the food composition of the present invention.
  • the cosmetic composition is a lotion, nutrition lotion, nutrition essence, massage cream, beauty bath additives, body lotion, body milk, bath oil, baby oil, baby powder, shower gel, shower cream, sunscreen lotion, sunscreen Creams, suntan creams, skin lotions, skin creams, sunscreen cosmetics, cleansing milk, depilatory ⁇ cosmetic ⁇ , face and body lotions, face and body creams, skin whitening creams, hand lotions, hair lotions, cosmetic creams, jasmine Oil, Bath Soap, Water Soap, Beauty Soap, Shampoo, Hand Cleanser (Hand Cleaner), Medicated Soap ⁇ Non-Medical ⁇ , Cream Soap, Facial Wash, Systemic Cleanser, Scalp Cleaner, Hairrin, Cosmetic Soap, Tooth Whitening Gel, Toothpaste Or the like.
  • the composition of the present invention may further comprise a solvent or a suitable carrier, excipient or diluent commonly used in the preparation of the cosmetic composition.
  • the kind of the solvent that can be further added in the cosmetic composition of the present invention is not particularly limited, but, for example, water, saline, DMSO, or a combination thereof may be used, and as the carrier, excipient or diluent, purified water, oil, wax , Fatty acids, fatty acid alcohols, fatty acid esters, surfactants, humectants, thickeners, antioxidants, viscosity stabilizers, chelating agents, buffers, lower alcohols, and the like.
  • a whitening agent, a moisturizing agent, vitamins, sunscreens, perfumes, dyes, antibiotics, antibacterial agents, antifungal agents may be included as necessary.
  • the oil may be hydrogenated vegetable oil, castor oil, cottonseed oil, olive oil, palm oil, jojoba oil, avocado oil, wax, wax, carnauba, candelilla, montan, ceresin, liquid paraffin, lanolin Can be used.
  • Stearic acid, linoleic acid, linolenic acid, oleic acid may be used as fatty acids, cetyl alcohol, octyl dodecanol, oleyl alcohol, pantenol, lanolin alcohol, stearyl alcohol, hexadecanol may be used as fatty acid alcohol.
  • Isopropyl myristate, isopropyl palmitate, butyl stearate may be used as the fatty acid ester.
  • surfactants cationic surfactants, anionic surfactants and nonionic surfactants known in the art can be used, and surfactants derived from natural products are preferred as much as possible.
  • it may include a hygroscopic agent, a thickener, an antioxidant, and the like, which are widely known in the cosmetic field, and their types and amounts are known in the art.
  • composition provided by the present invention is very excellent in promoting hair growth and hair growth, and excellent in the prevention and treatment of hair loss, it is safe without side effects even when ingested or applied to the skin.
  • FIG. 1 is a graph showing the change in cell viability as a result of treating asparagus filtrate, caffeine, and mixtures thereof to dermal papilla cells in Experimental Example 1.
  • FIG. 1 is a graph showing the change in cell viability as a result of treating asparagus filtrate, caffeine, and mixtures thereof to dermal papilla cells in Experimental Example 1.
  • Figure 2 is a graph showing the change in the expression level of PTC-1, VEGF and CD34 gene as Experimental Example 2 treated asparagus filtrate, caffeine and mixtures thereof.
  • Figure 3 shows the changes after the treatment of asparagus filtrate, caffeine and mixtures of the dermal papilla cells in Experimental Example 3 by fluorescence immunostaining.
  • a pharmaceutical composition for preventing or treating hair loss including plant-derived extracellular vesicles and caffeine as an active ingredient.
  • the cells used human dermal palilla cells (DPC).
  • DPC human dermal palilla cells
  • the cells were carried out at passage passage 20 or less, and the culture medium was cultured in DMEM (welgene, Korea) medium in 10% FBS ( lonza), 1% penicillin-streptomycin (welgene, Korea) was used, and the cells were incubated in 37 ° C., 5% CO 2 incubator after inoculation into the medium.
  • the liquid plant juice obtained by juiced with a low speed screw with a stirring speed of 40 rpm was filtered through a sieve to remove the suspended matter. Thereafter, the mixture was allowed to stand at 25 ° C. for 10 minutes, centrifuged at 2,000 g for 30 minutes to separate the supernatant, and then filtered through a filtration membrane containing 0.45 ⁇ m pores of polyvinylidene difluoride. Filtrate was obtained by filtration with a filtration membrane containing 0.22 ⁇ m pores.
  • Dermal papilla cells 2.5 ⁇ 10 4 cells were equally dispensed into each 24-well plate (SPL, Korea). After 24 hours of stabilization time, the filtrate, caffeine and mixtures thereof obtained in Preparation Example 1 were treated for 48 hours. Dilute the MTS reagent (Promega, USA) and the cell's basic medium (FBS free, 1% p / s) at a ratio of 1: 5 and dispense 500 ⁇ l per well for 1 hour 30 minutes to absorb the absorbance at 490nm. The change in cell viability was measured and the results are shown graphically in FIG. 1. However, 10% fetal bovine serum (FBS) was treated as a positive control, and no treatment was performed as a negative control.
  • FBS fetal bovine serum
  • synergistic effect can be obtained in the improvement of the dermal papilla cell proliferation rate when the mixture is treated as in the present invention than when the plant-derived extracellular vesicles or caffeine are treated alone.
  • RNA isolation kit Quiagen, USA
  • primers for 1 ⁇ g of RNA isolated using a cDNA synthesis kit were synthesized.
  • the primer was used at a concentration of 10 pmol / ⁇ l and 2X Cyber Green Master Mix (Takara, Japan) was added to detect the degree of PTC-1 (the patched protein-1), VEGF (Vascular endothelial growth factor) and CD34 gene expression.
  • PTC-1 the patched protein-1
  • VEGF Vascular endothelial growth factor
  • CD34 gene expression The results are shown graphically in FIG. However, no treatment was performed as a control.
  • PTC-1 is a Sonic Hedgehog (Shh) receptor, a gene that controls the formation and growth of hair follicles, VEGF is a gene related to vascular growth factors, CD34 corresponds to an angiogenesis marker.
  • Sh Sonic Hedgehog
  • the mixed composition of the plant-derived extracellular vesicles and caffeine according to the present invention has excellent hair growth and hair growth promoting effects.
  • the mixed composition of the plant-derived extracellular vesicles and caffeine according to the present invention has a significant effect on the growth and development of dermal papilla cells than when each of them is treated alone.
  • the present invention includes a plant juice-derived extracellular vesicles and caffeine, provides a composition for the prevention or treatment of hair loss excellent in hair growth and hair growth promoting effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition pour prévenir ou traiter la perte des cheveux, comprenant des vésicules extracellulaires dérivées de plantes et de la caféine. La composition de la présente invention présente un excellent effet de stimulation de la pousse des cheveux et présente donc d'excellents effets de prévention et de traitement de la perte des cheveux et peut être ingérée ou appliquée sur la peau de façon sûre, sans effets indésirables.
PCT/KR2016/010664 2015-09-25 2016-09-23 Composition pour prévenir ou traiter la perte des cheveux WO2017052271A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020150136902A KR101897451B1 (ko) 2015-09-25 2015-09-25 탈모의 예방 또는 치료용 조성물
KR10-2015-0136902 2015-09-25

Publications (1)

Publication Number Publication Date
WO2017052271A1 true WO2017052271A1 (fr) 2017-03-30

Family

ID=58386546

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/010664 WO2017052271A1 (fr) 2015-09-25 2016-09-23 Composition pour prévenir ou traiter la perte des cheveux

Country Status (2)

Country Link
KR (1) KR101897451B1 (fr)
WO (1) WO2017052271A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019229271A1 (fr) * 2018-06-01 2019-12-05 Alexander May Microvésicules dérivées de produits à base de plantes fermentées, leur procédé de préparation et d'utilisation
WO2021045712A1 (fr) * 2019-09-02 2021-03-11 Yeditepe Universitesi Utilisation d'exosomes végétaux pour améliorer la viabilité et la capacité de croissance capillaire de cellules cutanées
WO2024077862A1 (fr) * 2022-10-09 2024-04-18 济宁医学院 Utilisation de vésicules extracellulaires de gingembre dans la préparation d'un médicament pour favoriser la prolifération de cellules souches de follicules pileux

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019066121A1 (fr) * 2017-09-28 2019-04-04 ㈜프로스테믹스 Composition comprenant des vésicules extracellulaires dérivées de plantes
KR102090008B1 (ko) * 2019-01-30 2020-03-18 주식회사 리더스코스메틱 플럼코트 추출물을 유효성분으로 함유하는 탈모 방지용 화장료 조성물
WO2022164183A1 (fr) * 2021-01-26 2022-08-04 주식회사 리스큐어바이오사이언시스 Composition pour favoriser la pousse des cheveux comprenant des vésicules extracellulaires dérivées de lactobacillus curvatus en tant que principe actif
KR102638147B1 (ko) * 2021-08-25 2024-02-19 충남대학교 산학협력단 망고 추출물을 포함하는 탈모 방지용 조성물
KR102527607B1 (ko) 2022-06-30 2023-05-03 (주)모아캠 식물 유래 세포외소포체, 이를 포함하는 조성물, 및 이의 제조방법
KR102510870B1 (ko) * 2022-12-14 2023-03-17 유스킨컴퍼니 주식회사 펩타이드를 포함하는 육모촉진용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012703A1 (fr) * 1991-01-15 1992-08-06 University Of Miami Stimulation de la croissance des cheveux par application de phospholipides
US20070077222A1 (en) * 2005-10-03 2007-04-05 Shapiro Steven D Composition and treatment for hair loss

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012703A1 (fr) * 1991-01-15 1992-08-06 University Of Miami Stimulation de la croissance des cheveux par application de phospholipides
US20070077222A1 (en) * 2005-10-03 2007-04-05 Shapiro Steven D Composition and treatment for hair loss

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FISCHER, T. W. ET AL.: "Differential Effects of Caffeine on Hair Shaft Elongation, Matrix and Outer Root Sheath Keratinocyte Proliferation, and Transforming Growth Factor-b2/insulin-like Growth Factor-1-mediated Regulation ot the Hair Cycle in Male and Female Human Hair Follicles In Vitro", vol. 171, 2014, pages 1031 - 1043, XP055371232 *
JU, S. ET AL.: "Grape Exosome-like Nanoparticles Induce Intestinal Stem Cells and Protect Mice from DSS-induced Colitis", MOLECULAR THERAPY, vol. 21, no. 7, 2013, pages 1345 - 1357, XP055300276 *
QUESENBERRY, P. J. ET AL.: "Potential Functional Applications of Extracellular Vesicles: a Report by the NIH Common Fund Extracellular Rna Communication Consortium", JOURNAL OF EXTRACELLULAR VESICLES, vol. 4, no. 27575, 28 August 2015 (2015-08-28), pages 1 - 11, XP055371234 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019229271A1 (fr) * 2018-06-01 2019-12-05 Alexander May Microvésicules dérivées de produits à base de plantes fermentées, leur procédé de préparation et d'utilisation
WO2021045712A1 (fr) * 2019-09-02 2021-03-11 Yeditepe Universitesi Utilisation d'exosomes végétaux pour améliorer la viabilité et la capacité de croissance capillaire de cellules cutanées
EP4025232A4 (fr) * 2019-09-02 2024-02-07 Yeditepe Universitesi Utilisation d'exosomes végétaux pour améliorer la viabilité et la capacité de croissance capillaire de cellules cutanées
WO2024077862A1 (fr) * 2022-10-09 2024-04-18 济宁医学院 Utilisation de vésicules extracellulaires de gingembre dans la préparation d'un médicament pour favoriser la prolifération de cellules souches de follicules pileux

Also Published As

Publication number Publication date
KR101897451B1 (ko) 2018-09-12
KR20170037381A (ko) 2017-04-04

Similar Documents

Publication Publication Date Title
WO2017052271A1 (fr) Composition pour prévenir ou traiter la perte des cheveux
WO2017052267A1 (fr) Composition comprenant des vésicules extracellulaires dérivées d'extrait de plante destinée à l'état de la peau et à prévenir la perte de cheveux
WO2019066538A1 (fr) Composition comprenant des vésicules extracellulaires dérivées de plantes
WO2016159567A2 (fr) Composition pour favoriser la croissance capillaire ou la régénération capillaire, et à effet anti-inflammatoire
WO2016056781A1 (fr) Composition pour prévenir la chute des cheveux ou stimuler la pousse des cheveux comprenant un extrait d'artemisia umbelliformis
KR102603262B1 (ko) 필발 추출물을 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 조성물
WO2019168348A1 (fr) Composition de prévention de la chute des cheveux et de stimulation de la pousse des cheveux
KR101541470B1 (ko) 진세노사이드 ｆ2를 포함하는 탈모방지 또는 발모촉진용 조성물
KR102612128B1 (ko) 조팝나무 추출물을 유효성분으로 함유하는 탈모방지 및 모발 성장용 조성물
WO2016056780A1 (fr) Composition pour prévenir la chute des cheveux ou stimuler la pousse des cheveux comprenant un extrait de scutellaria alpina
WO2023022540A1 (fr) Composition de prévention de la perte de cheveux ou favorisant la pousse des cheveux comprenant un extrait de fleur de chardon-marie comme ingrédient actif
WO2021215882A1 (fr) Composition pour prévenir la chute des cheveux ou favoriser la pousse des cheveux comprenant un extrait de péricarpe de camélia en tant que principe actif
KR101701217B1 (ko) 밤송이로부터 추출된 물질을 함유하는 탈모 예방 또는 치료용 약학 조성물
WO2015005700A1 (fr) Composition permettant de favoriser la repousse des cheveux et la croissance des cheveux
KR20210025155A (ko) 수벌번데기 추출물을 포함하는 탈모방지 또는 육모촉진용 조성물
WO2015030422A1 (fr) Composition pour accélérer la restauration des cheveux ou la croissance des cheveux, comprenant du 21-o-angéloylthéasapogénol e3
WO2019164090A1 (fr) Composition contenant un extrait de symplocarpe fétide ou une fraction de celui-ci utilisé comme principe actif pour l'atténuation des rides
KR102597791B1 (ko) 보리밥나무 추출물 또는 그 분획물을 포함하는 탈모 예방 또는 발모촉진용 조성물
KR20170117929A (ko) 산삼 유래 세포 외 소포체를 포함하는 상처 치료용 조성물
KR102625895B1 (ko) 광나무 추출물 또는 그 분획물을 포함하는 탈모 예방또는 발모촉진용 조성물
WO2023106879A1 (fr) Composition comprenant un extrait de cassia mimosoides en tant que principe actif pour améliorer l'état des cheveux ou du cuir chevelu
WO2010005256A2 (fr) Composition de prévention de la chute des cheveux ou de stimulation de la pousse des cheveux contenant un extrait issu de fruits et de graines de crataegus pinnatifida
KR101609436B1 (ko) 갈고리가시우무 추출물을 포함하는 탈모 방지 또는 육모 촉진을 위한 조성물
WO2021167269A1 (fr) Composition de blanchiment contenant un extrait de noyau de prune en tant que principe actif
WO2023149639A1 (fr) Composition pour prévenir la chute des cheveux ou favoriser la pousse des cheveux comprenant un extrait de persicaria pubescens en tant que principe actif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16848996

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16848996

Country of ref document: EP

Kind code of ref document: A1